All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
ELN-refined 2024 Beat-AML risk stratification for older patients with newly diagnosed AML
Bookmark this article
|
Prognostic impact of the 2022 ELN risk classification and development of a refined BEAT-AML 2024 risk stratification for older patients (aged ≥60 years) with ND AML receiving LIT were published by Hoff et al.1 in Blood Advances. A total of 595 patients with ND AML from the Beat AML trial (NCT03013998) were included; the median age was 73 years, and 42% were female. |
| Key learnings |
| According to the 2022 ELN risk stratification, 78% of patients were classified as adverse risk, 11% as favorable risk, and 11% as intermediate risk. Among 579 patients with OS data, ELN criteria did not distinguish between favorable- and intermediate-risk groups (p = 0.71) but predicted poor OS in those with adverse risk (p < 0.001; C-index: 0.55), with 2-year OS of 47% vs 50% vs 23%, respectively. |
| Multivariable analysis of the training set (n = 316) identified IDH2 mutation as an independent favorable prognostic factor, while KRAS, MLL2, and TP53 mutations were independent unfavorable (p < 0.05). |
| A refined Beat-AML 2024 risk stratification resulted in a “mutation score” that classified patients into two risk groups: −1 to 0 points (Beat-AML intermediate; 41%) vs 1+ points (Beat-AML adverse; 37%). The 2022 ELN favorable- and intermediate-risk patients were reclassified as Beat-AML favorable-risk (22%). |
| The refined risk model showed stronger prognostication for OS, with 2-year OS rates of 48% vs 33% vs 11% in Beat-AML favorable-, intermediate-, and adverse-risk groups, respectively; (p < 0.001; C-index: 0.60). |
| The Beat-AML 2024 model redefines risk for older patients with ND AML undergoing LIT and informs treatment decisions. Further validation of the model is warranted. |
Abbreviations: AML, acute myeloid leukemia; ELN, European LeukemiaNet; LIT, lower-intensity treatment; ND, newly diagnosed; OS, overall survival.
- Hoff FW, Blum WG, Huang Y, et al. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024;8(20):5297-5305. DOI: 10.1182/bloodadvances.2024013685.
Your opinion matters
15 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox